Curaleaf-Aurora Hostile Takeover Bid: Timeline, Analysis & Implications

Executive Summary

Aurora Cannabis has filed an application with the Alberta Securities Commission challenging the adequacy of disclosure in Curaleaf Holdings' unsolicited takeover bid, marking a significant escalation in what has become the cannabis industry's highest-profile hostile acquisition attempt. The filing, submitted September 23, 2026, identifies what Aurora characterizes as "several deficiencies" in the disclosure documents Curaleaf provided to Aurora shareholders as part of its bid to acquire the Canadian licensed producer. This regulatory challenge represents Aurora's most aggressive defensive maneuver since Curaleaf publicly announced its hostile offer, and sets the stage for a protracted battle that could reshape the North American cannabis consolidation landscape. The dispute centers on whether Curaleaf has provided sufficient information for Aurora shareholders to make an informed decision about tendering their shares, with implications extending far beyond the two companies to affect cross-border cannabis M&A strategy, regulatory harmonization between U.S. and Canadian securities frameworks, and the future structure of multi-state operator expansion into international markets.

Why This Matters

The Curaleaf-Aurora confrontation represents the first major hostile takeover attempt in the cannabis industry involving a U.S. multi-state operator targeting a Canadian licensed producer, creating precedent that will influence billions of dollars in future cross-border consolidation. For shareholders, the outcome will determine whether Aurora remains independent or becomes part of Curaleaf's North American platform, affecting approximately 320,000 retail investors across both companies. The transaction's proposed equity value of approximately $2.1 billion would create the world's largest vertically integrated cannabis company by revenue, with combined annual sales exceeding $1.8 billion and operations spanning 23 U.S. states plus international medical markets.

For the broader cannabis industry, this bid tests whether U.S. operators can successfully execute hostile acquisitions of Canadian targets despite the regulatory complexity created by cannabis remaining federally illegal in the United States under the Controlled Substances Act (21 U.S.C. § 812). The Alberta Securities Commission's handling of Aurora's disclosure complaint will establish important precedent for how Canadian provincial regulators evaluate takeover bid documentation from U.S. cannabis companies that cannot list on major U.S. exchanges due to federal prohibition.

The business implications extend to capital allocation strategy across the sector. If Curaleaf succeeds, it validates hostile M&A as a viable tool for U.S. operators seeking to acquire undervalued Canadian assets, potentially triggering a wave of similar unsolicited bids. If Aurora successfully defends its independence, it reinforces the difficulty of executing cross-border cannabis acquisitions without target board support, likely pushing the industry toward negotiated transactions with higher premiums.

Background and History

Origins of the Two Companies

Curaleaf Holdings was founded in 2010 and grew through aggressive acquisition to become the largest U.S. cannabis company by revenue, while Aurora Cannabis emerged from the 2006 founding of a small British Columbia medical marijuana operation to become one of Canada's dominant licensed producers before the 2018 adult-use legalization. Curaleaf went public on the Canadian Securities Exchange in October 2018 through a reverse takeover transaction, establishing its ticker symbol CURA. The company built its footprint through more than 60 acquisitions between 2018 and 2025, including the $875 million purchase of Grassroots in 2020 and the $286 million acquisition of Tryke Companies in 2024. By mid-2026, Curaleaf operated 151 dispensaries across the United States and maintained cultivation and processing facilities in 19 states.

Aurora Cannabis began trading on the Toronto Stock Exchange in July 2017 following its qualifying transaction, using ticker symbol ACB. The company pursued an aggressive international expansion strategy between 2017 and 2019, acquiring licensed producers across Europe and Latin America and investing heavily in large-scale greenhouse cultivation capacity. Aurora's market capitalization peaked at approximately $12 billion Canadian in March 2019, making it briefly the world's most valuable cannabis company. However, the company faced significant challenges following Canada's October 2018 adult-use legalization, including slower-than-expected market development, pricing pressure from illicit competition, and operational difficulties integrating its numerous acquisitions.

Aurora's Restructuring Period

Between 2020 and 2024, Aurora underwent a comprehensive restructuring that included facility closures, workforce reductions, and asset sales to address its cost structure and debt burden. The company closed 15 production facilities, reduced its workforce by approximately 2,100 employees, and sold its Danish and Uruguayan operations. Aurora's share price declined from a peak of approximately $140 Canadian (split-adjusted) in March 2019 to below $4 Canadian by early 2026, creating what some analysts characterized as a significant valuation discount relative to the company's remaining assets and market position.

By the second quarter of 2026, Aurora had stabilized its operations with positive adjusted EBITDA, a streamlined facility footprint focused on its core Canadian medical and adult-use business, and growing international medical cannabis export revenue. The company maintained the second-largest market share in the Canadian adult-use market at approximately 11 percent and held significant cultivation capacity that remained underutilized due to market oversupply conditions.

Curaleaf's International Ambitions

Curaleaf began exploring international expansion opportunities in 2023 as the U.S. federal rescheduling process stalled and the company sought growth avenues beyond its domestic footprint. The company established a European medical cannabis division through a partnership with a German pharmaceutical distributor in early 2024 and began evaluating acquisition targets in Canada, where licensed producers traded at significant discounts to their U.S. counterparts despite holding valuable production licenses, established brands, and international export capabilities.

Internal Curaleaf strategy documents from mid-2025, later disclosed in securities filings, identified Aurora as an attractive target due to its undervalued cultivation infrastructure, established European medical cannabis relationships, and potential synergies with Curaleaf's U.S. retail network for brand development. Curaleaf executives believed Aurora's depressed valuation created an opportunity to acquire production capacity and international market access at a fraction of replacement cost.

Initial Approach and Rejection

According to subsequent regulatory filings, Curaleaf first approached Aurora's board of directors in March 2026 with a confidential proposal to acquire the company in an all-stock transaction valuing Aurora at $6.50 Canadian per share, representing a 35 percent premium to the then-current trading price. Aurora's board, advised by BMO Capital Markets and Canaccord Genuity, rejected the proposal on April 12, 2026, stating that the offer significantly undervalued the company and its strategic prospects.

Curaleaf increased its offer to $7.25 Canadian per share in a revised proposal submitted May 8, 2026, which Aurora's board again rejected on May 29, 2026. Following this second rejection, Curaleaf's management team made the strategic decision to take the offer directly to Aurora shareholders through a formal takeover bid, bypassing the target company's board.

Public Announcement of Hostile Bid

On July 15, 2026, Curaleaf publicly announced its intention to make a formal takeover bid for all outstanding Aurora common shares at $7.50 Canadian per share in Curaleaf subordinate voting shares, valuing the transaction at approximately $2.1 billion. The announcement sent Aurora's share price up 42 percent to $7.35 Canadian, while Curaleaf's shares declined 8 percent on concerns about dilution and execution risk. The proposed exchange ratio of 0.1875 Curaleaf subordinate voting shares for each Aurora common share implied significant dilution for existing Curaleaf shareholders, who would own approximately 62 percent of the combined entity with Aurora shareholders receiving 38 percent.

Aurora's board immediately issued a statement advising shareholders to take no action, stating that the board would review the offer with its financial and legal advisors and provide a formal recommendation. The company also implemented a shareholder rights plan, commonly known as a poison pill, designed to prevent Curaleaf from acquiring control without providing adequate time for the board to explore alternatives.

Regulatory Filings and Disclosure

Curaleaf filed its formal takeover bid circular with Canadian securities regulators on August 19, 2026, commencing a 105-day offer period during which Aurora shareholders could tender their shares. The circular included financial projections for the combined entity, descriptions of anticipated synergies, and disclosure regarding Curaleaf's business, financial condition, and the risks associated with the transaction. Under Canadian securities law, specifically National Instrument 62-104, takeover bids must remain open for a minimum period and provide detailed disclosure to enable shareholders to make informed decisions.

Aurora filed its directors' circular on September 3, 2026, formally recommending that shareholders reject Curaleaf's offer. The circular, prepared with assistance from Aurora's financial advisors, argued that the bid significantly undervalued Aurora's assets, failed to reflect the company's improving operational performance, and exposed Aurora shareholders to excessive risk from Curaleaf's U.S. operations, which remain subject to federal prohibition and potential enforcement action.

The September 23 ASC Application

Aurora's September 23, 2026 application to the Alberta Securities Commission represents a significant escalation in the company's defense strategy. The application requests that the ASC issue a cease trade order preventing further share tenders until Curaleaf addresses the alleged disclosure deficiencies. While the specific deficiencies have not been publicly detailed, securities law experts suggest they likely relate to Curaleaf's financial projections, the methodology used to calculate anticipated synergies, disclosure regarding regulatory risks in U.S. markets, or the treatment of contingent liabilities.

Key Players

Curaleaf Holdings

Curaleaf Holdings operates as the largest vertically integrated cannabis company in the United States by revenue, with executive chairman Boris Jordan and CEO Matt Darin leading the strategic direction that resulted in the Aurora bid. Jordan, a Russian-American businessman who previously worked in investment banking and private equity, has served as Curaleaf's executive chairman since the company's founding and controls approximately 28 percent of voting shares through super-voting stock. Darin joined as CEO in January 2024 after serving as chief strategy officer and has championed international expansion as a key growth driver.

The company reported revenue of $1.38 billion for the twelve months ending June 30, 2026, with operations in 23 states including major markets such as Florida, New York, Pennsylvania, and Illinois. Curaleaf's business model emphasizes vertical integration, with the company cultivating, processing, and retailing cannabis products through its owned-and-operated dispensaries. The company trades on the Canadian Securities Exchange under ticker CURA and on the OTCQX market in the United States under ticker CURLF, as it cannot list on the New York Stock Exchange or Nasdaq due to cannabis remaining federally illegal.

Aurora Cannabis

Aurora Cannabis operates under the leadership of CEO Miguel Martin, who joined the company in September 2020 from Altria Group and led the restructuring that returned the company to profitability. The company's board of directors, chaired by Michael Singer, includes nine members with backgrounds in pharmaceuticals, consumer packaged goods, and finance. The board's special committee evaluating Curaleaf's bid consists of independent directors Ronald Funk, Norma Beauchamp, and Lance Friedmann.

Aurora reported net revenue of $251 million Canadian for the fiscal year ending March 31, 2026, with operations focused on the Canadian medical and adult-use markets plus growing international medical cannabis sales to Germany, Australia, and the United Kingdom. The company operates primary cultivation facilities in Alberta and Ontario with approximately 1.2 million square feet of licensed production space. Aurora trades on the Toronto Stock Exchange under ticker ACB and on the Nasdaq under ticker ACB, maintaining its U.S. listing because it operates only in jurisdictions where cannabis is legal under local law.

Alberta Securities Commission

The Alberta Securities Commission serves as the provincial securities regulator for Alberta and has jurisdiction over Aurora's takeover bid defense because Aurora is headquartered in Edmonton. The ASC operates under the Securities Act (Alberta) and has authority to issue cease trade orders, require additional disclosure, and impose conditions on takeover bids to protect shareholders. The commission's decisions in takeover bid disputes typically focus on whether disclosure documents provide sufficient information for shareholders to make informed decisions, rather than evaluating the fairness of the offer price.

Chair Stan Magidson leads the ASC, which has historically taken an active role in reviewing takeover bid disclosure and has issued cease trade orders in previous cases where bidders failed to provide adequate information. The commission's handling of Aurora's application will be closely watched as precedent for cross-border cannabis M&A transactions.

Financial and Legal Advisors

Aurora retained BMO Capital Markets and Canaccord Genuity as financial advisors to evaluate Curaleaf's offer and provide fairness opinions. The company's legal counsel includes Stikeman Elliott in Canada and Sullivan & Cromwell in the United States. Curaleaf engaged Jefferies LLC and Cowen and Company as financial advisors and retained Goodmans LLP as Canadian legal counsel and Skadden, Arps, Slate, Meagher & Flom as U.S. legal counsel.

Legal and Regulatory Framework

Canadian Takeover Bid Rules

Canadian takeover bids are governed by National Instrument 62-104, which establishes minimum bid periods, disclosure requirements, and procedural protections for target company shareholders. The instrument requires that takeover bids remain open for at least 105 days and that bidders provide detailed disclosure regarding their business, financial condition, the consideration being offered, and the effects of the transaction. Bids must be extended for an additional 10 days following any variation in terms, and shareholders who have already tendered must be permitted to withdraw their shares during specified withdrawal periods.

Provincial securities commissions have authority under their respective securities acts to review takeover bid disclosure and issue cease trade orders where disclosure is deficient. The Alberta Securities Commission can exercise this authority under Section 198 of the Securities Act (Alberta), which permits the commission to order that trading in securities cease where it is in the public interest to do so. The commission's analysis typically focuses on whether the disclosure enables shareholders to make informed decisions, considering factors such as the completeness of financial information, the reasonableness of projections, and the adequacy of risk disclosure.

Shareholder Rights Plans

Aurora's shareholder rights plan, adopted in response to Curaleaf's initial approach, operates as a defensive mechanism designed to give the board time to evaluate alternatives and negotiate with potential bidders. The plan, commonly called a poison pill, grants existing shareholders rights to purchase additional shares at a discount if any person acquires more than 20 percent of Aurora's outstanding shares without board approval. Canadian courts have generally upheld shareholder rights plans as valid defensive tactics, provided they are not used to entrench management and are subject to shareholder approval within six months of adoption.

However, rights plans do not prevent takeover bids that comply with securities law requirements and do not provide absolute protection against hostile offers. Curaleaf's bid, structured to comply with National Instrument 62-104, can proceed despite the rights plan, though the plan prevents Curaleaf from acquiring shares through market purchases or private transactions while the bid is outstanding.

Cross-Border Regulatory Complexity

The transaction's cross-border structure creates unique regulatory complexity because cannabis remains illegal under U.S. federal law pursuant to the Controlled Substances Act, while Canada legalized adult-use cannabis through the Cannabis Act (S.C. 2018, c. 16) in October 2018. This creates several legal issues that affect disclosure requirements and transaction execution.

First, Curaleaf cannot list its shares on major U.S. exchanges such as the New York Stock Exchange or Nasdaq because those exchanges require compliance with federal law, and cannabis companies violate the Controlled Substances Act. Aurora shareholders receiving Curaleaf shares in the transaction would hold securities that trade only on the Canadian Securities Exchange and the OTCQX market, potentially reducing liquidity compared to Aurora's current Nasdaq listing.

Second, the combined entity would face ongoing federal illegality risk in its U.S. operations, including potential asset forfeiture under 21 U.S.C. § 881, prosecution under 21 U.S.C. § 841, and banking restrictions under federal money laundering statutes. These risks require extensive disclosure in takeover bid documents, and Aurora has argued that Curaleaf's disclosure inadequately addresses the magnitude and likelihood of federal enforcement.

Third, the transaction raises questions about how Canadian securities regulators should evaluate bids from companies whose core business violates the laws of their home jurisdiction. While the CSA has permitted U.S. cannabis companies to list on Canadian exchanges, the appropriate standard for takeover bid disclosure remains unsettled.

Disclosure Obligations

National Instrument 62-104 requires that takeover bid circulars include detailed disclosure regarding the bidder's business, financial condition, and prospects, as well as the effects of the transaction on target shareholders. Specific requirements include audited financial statements, management's discussion and analysis, descriptions of material contracts, and disclosure of risks that could affect the value of the consideration being offered. The instrument also requires disclosure of any material changes in the bidder's business or financial condition that occur during the offer period.

Where the consideration consists of securities, as in Curaleaf's all-stock offer, the disclosure requirements are particularly extensive because target shareholders are being asked to exchange their current holdings for securities of a different company. The disclosure must enable shareholders to assess the value and risks of the securities they would receive, which requires comprehensive information about the bidder's operations, financial performance, and risk factors.

Market and Business Implications

Valuation and Deal Economics

At the proposed exchange ratio of 0.1875 Curaleaf subordinate voting shares per Aurora common share, the transaction implies a value of approximately $7.50 Canadian per Aurora share based on Curaleaf's trading price at the time of announcement. This represented a 42 percent premium to Aurora's undisturbed trading price of $5.28 Canadian on July 14, 2026, but Aurora's board and financial advisors have argued the offer significantly undervalues the company's assets and prospects.

BMO Capital Markets' analysis, disclosed in Aurora's directors' circular, valued Aurora's standalone business at between $8.25 and $10.50 Canadian per share using a combination of discounted cash flow analysis, comparable company trading multiples, and precedent transaction multiples. The analysis highlighted Aurora's underutilized cultivation capacity, which could support significantly higher production volumes as Canadian market demand grows, and the company's international medical cannabis relationships, which provide access to higher-margin export markets.

Curaleaf's financial projections for the combined entity, disclosed in its takeover bid circular, anticipate annual cost synergies of $175 million within two years of closing, primarily from consolidating cultivation operations, eliminating duplicative corporate overhead, and optimizing the combined company's supply chain. The projections also assume revenue synergies of $85 million annually from leveraging Aurora's brands in Curaleaf's U.S. retail network and expanding international medical cannabis sales through Curaleaf's distribution relationships.

Impact on MSO Consolidation Strategy

The Curaleaf-Aurora bid represents a potential shift in multi-state operator growth strategy from domestic expansion to international diversification. U.S. cannabis companies have historically focused on acquiring additional state licenses and building vertically integrated operations within the United States, with limited international activity beyond exploratory investments. Curaleaf's hostile bid for Aurora signals that some MSOs now view Canadian licensed producers as attractive acquisition targets that offer production capacity, international market access, and brand portfolios at valuations well below U.S. comparables.

If the transaction succeeds, it could trigger additional cross-border M&A activity as other MSOs evaluate similar opportunities. Trulieve Cannabis, Green Thumb Industries, and Verano Holdings have all been identified by analysts as potential acquirers of Canadian licensed producers, with Tilray Brands, Organigram Holdings, and Hexo Corp frequently mentioned as potential targets. The Canadian cannabis sector's aggregate market capitalization of approximately $8 billion as of September 2026 makes it accessible to the largest U.S. operators, which have enterprise values ranging from $3 billion to $8 billion.

280E Tax Implications

The combined entity would face continued application of Internal Revenue Code Section 280E, which prohibits businesses trafficking in controlled substances from deducting ordinary business expenses for federal tax purposes. Section 280E has created effective tax rates exceeding 70 percent for many U.S. cannabis operators, significantly reducing profitability and cash flow. Curaleaf paid approximately $385 million in federal income taxes on $1.38 billion in revenue for the twelve months ending June 30, 2026, representing an effective tax rate of approximately 28 percent of revenue despite reporting GAAP net income of only $127 million.

Aurora's Canadian operations are not subject to Section 280E and benefit from normal corporate tax treatment, with the company paying Canadian federal and provincial income taxes at a combined statutory rate of approximately 26.5 percent on taxable income. The acquisition would not change the tax treatment of Aurora's Canadian operations, but it would subject the combined entity to continued 280E exposure on its U.S. business, potentially reducing the after-tax value of anticipated synergies.

Capital Markets Access

The transaction would affect Aurora shareholders' liquidity and access to capital markets. Aurora currently trades on both the Toronto Stock Exchange and Nasdaq, providing access to a broad base of institutional and retail investors. Curaleaf trades only on the Canadian Securities Exchange and the OTCQX market, with significantly lower trading volumes and institutional participation. Aurora shareholders receiving Curaleaf shares would hold securities with reduced liquidity and limited access to U.S. institutional investors who cannot hold OTCQX-listed securities due to investment policy restrictions.

This liquidity differential has been a central argument in Aurora's opposition to the bid, with the company's directors' circular emphasizing that shareholders would exchange TSX and Nasdaq-listed shares for CSE and OTCQX-listed shares with lower trading volumes and institutional ownership. Curaleaf has countered that the combined entity's larger scale and improved financial performance would attract greater institutional interest despite the listing limitations.

What Experts Say

Securities law experts have characterized Aurora's Alberta Securities Commission application as a standard defensive tactic in hostile takeover situations, though the cross-border cannabis context creates unique disclosure challenges. According to Anita Anand, a professor at the University of Toronto Faculty of Law who specializes in securities regulation, target companies frequently challenge bidder disclosure as a means of delaying transactions and creating negotiating leverage. Anand noted in a September 2026 interview with Bloomberg that the ASC will focus its analysis on whether Curaleaf's disclosure enables Aurora shareholders to make informed decisions, rather than evaluating the fairness of the offer price.

Investment analysts covering the cannabis sector have expressed mixed views on the transaction's strategic logic and likelihood of success. Vivien Azer, managing director at Cowen and Company, stated in a research note that the combination would create meaningful scale advantages and cost synergies, but questioned whether Curaleaf's shares provide sufficient value given their OTCQX listing and federal illegality risk. Azer maintained a neutral rating on both companies pending resolution of the disclosure dispute and Aurora's board recommendation.

Matt Bottomley, director of equity research at Canaccord Genuity, argued in a September 2026 report that Aurora's standalone valuation does not reflect the company's improving fundamentals and international growth potential. According to Bottomley, Aurora's international medical cannabis revenue grew 47 percent year-over-year in the most recent quarter, and the company's cultivation capacity positions it to capture market share as Canadian demand recovers from current oversupply conditions. Bottomley valued Aurora at $9.25 Canadian per share on a standalone basis, well above Curaleaf's $7.50 offer.

Legal practitioners specializing in cross-border M&A have noted that the transaction tests unresolved questions about how Canadian securities regulators should evaluate bids from U.S. cannabis companies. According to Jeffrey Singer, a partner at Stikeman Elliott who is not involved in the transaction, Canadian securities law requires disclosure that enables shareholders to assess the value and risks of the consideration being offered, but there is limited precedent for how to apply this standard when the bidder's core business violates U.S. federal law. Singer stated in a Canadian Lawyer interview that the ASC's decision could establish important guidance for future cross-border cannabis transactions.

What's Next

The Alberta Securities Commission will review Aurora's application and determine whether to issue a cease trade order, request additional disclosure from Curaleaf, or dismiss the application, with a decision expected within 30 to 45 days. If the ASC identifies disclosure deficiencies, it could require Curaleaf to amend its takeover bid circular and extend the offer period to provide shareholders additional time to review the supplemental disclosure. Such an outcome would delay the transaction and potentially provide Aurora's board additional time to solicit alternative proposals or implement other defensive measures.

The takeover bid's current expiry date is December 2, 2026, though Curaleaf has the right to extend the offer period if conditions are not satisfied. The bid is conditional on Curaleaf receiving tenders representing at least 66.67 percent of Aurora's outstanding shares, obtaining necessary regulatory approvals, and the absence of material adverse changes in Aurora's business. As of September 23, 2026, Curaleaf had not disclosed how many Aurora shares had been tendered to the offer.

Aurora's board continues to explore strategic alternatives with its financial advisors, including potential negotiations with Curaleaf on improved terms, solicitation of competing bids from other potential acquirers, or implementation of a standalone strategic plan designed to realize value for shareholders without a sale transaction. The company's shareholder rights plan remains in effect and would require shareholder approval at Aurora's annual meeting scheduled for November 2026 to remain valid beyond six months from adoption.

Several potential outcomes could emerge over the coming months. First, the ASC could require supplemental disclosure from Curaleaf, which could lead to negotiations between the companies on improved terms or additional deal protections for Aurora shareholders. Second, a competing bidder could emerge with a superior proposal, potentially triggering a bidding contest that would benefit Aurora shareholders. Third, Curaleaf could increase its offer price or modify the consideration to address Aurora's valuation concerns. Fourth, the bid could fail if insufficient Aurora shareholders tender their shares by the expiry date, leaving Aurora independent and potentially vulnerable to future acquisition attempts.

The broader cannabis industry will closely monitor the transaction's progression as an indicator of whether hostile M&A becomes a viable tool for sector consolidation. If Curaleaf succeeds in acquiring Aurora despite board opposition, it could encourage other MSOs to pursue unsolicited bids for undervalued Canadian targets. If Aurora successfully defends its independence, it would reinforce the importance of board support in cannabis M&A and likely push future transactions toward negotiated deals with higher premiums.

Further Reading

• National Instrument 62-104 Take-Over Bids and Issuer Bids - https://www.osc.ca/en/securities-law/instruments-rules-policies/6/62-104
• Securities Act (Alberta), RSA 2000, c S-4 - https://www.canlii.org/en/ab/laws/stat/rsa-2000-c-s-4/latest/
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13-subchapI-partB-sec812.htm
• Cannabis Act (Canada), S.C. 2018, c. 16 - https://laws-lois.justice.gc.ca/eng/acts/c-24.5/
• Curaleaf Holdings SEDAR+ Profile - https://www.sedarplus.ca/landingpage/
• Aurora Cannabis SEDAR+ Profile - https://www.sedarplus.ca/landingpage/
• Alberta Securities Commission - https://www.asc.ca
• Internal Revenue Code Section 280E - https://www.law.cornell.edu/uscode/text/26/280E

Update — September 24, 2026: Aurora Files for Regulatory Protection Order

Aurora Cannabis filed a petition with Canadian securities regulators seeking a protective order against Curaleaf's hostile takeover bid, according to filings disclosed September 24, 2026. The company requested that regulators impose additional disclosure requirements on Curaleaf and potentially extend the minimum tender period beyond the standard 35-day window. Aurora's legal team argued that the cross-border nature of the bid creates informational asymmetries that disadvantage Canadian shareholders, particularly regarding Curaleaf's U.S. regulatory constraints and financing arrangements.

The filing specifically challenged Curaleaf's ability to complete the transaction, citing outstanding questions about Health Canada approval timelines and the bidder's compliance with Canadian securities law disclosure obligations. Aurora's counsel pointed to incomplete information about Curaleaf's debt covenants and whether existing lenders have consented to the acquisition financing structure. The petition requested that regulators require Curaleaf to disclose detailed pro forma financial statements showing the combined entity's debt service obligations under various cannabis price scenarios.

Aurora simultaneously announced it had retained a second financial advisor, Canaccord Genuity, to provide an independent fairness opinion on the hostile offer. The company's board said the dual-advisor approach would ensure thorough evaluation of strategic alternatives, including potential white knight bidders or asset sales. Chairman Michael Singer said the board "remains committed to maximizing shareholder value through all available means, including vigorous defense of this opportunistic bid."

Legal experts noted that Canadian securities regulators have broad discretion to impose conditions on takeover bids when shareholder protection concerns arise. The Ontario Securities Commission previously extended tender periods in three contested bids since 2024, adding an average of 21 additional days for target shareholders to evaluate competing proposals. For Aurora shareholders, the regulatory petition creates uncertainty about deal timing while potentially opening a window for competing offers or negotiated alternatives that could command a premium to Curaleaf's current bid price.